Project Grant R01CA301054

Award Date 4/1/25
Completion Date 3/31/30
Dollars Obligated $658K
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This National Cancer Institute (NCI) Project Grant award under the Cancer Biology Research program (CFDA 93.396) provides funding of $225,101 to Childrens Hospital Medical Center in Cincinnati, Ohio to create a comprehensive Splicing Neoantigen Atlas covering 30 adult and pediatric cancer types. The atlas and associated web portal called "NeoXplorer" will identify and validate thousands of highly shared splicing neoantigens across malignancies, determine their regulation and...
This $127,049.00 federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) aims to define the functional and spatial properties of tumor-specific tumor-infiltrating CD8 T cells. Specifically, the project will: Generate patient-derived xenograft (PDX) murine models of 3 melanoma patient tumors to test the required diversity of T cell receptors (TCRs) from tumor-infiltrating T cells needed to exert immune pressure on a heterogeneous tumor like...
The National Cancer Institute awarded The Johns Hopkins University a $443,191 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop engineered biomimetic tumor invasion models for screening chemotherapeutic agents against breast cancer metastasis. The project leverages expertise in cancer molecular biology, tissue engineering, machine learning, and drug development to create 2D and 3D tumor models that mimic the extracellular matrix and collective...
This $505,613 Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of statistical and computational approaches to utilize genomic data for precision cancer prevention at the Fred Hutchinson Cancer Center. The key objectives are to: (1) develop deep learning-based methods to identify tumor subtypes associated with poor outcomes and integrate external biomarker data to improve risk prediction; and (2)...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Northeastern University will develop a novel microfluidic droplet-based platform (MDP) technology to generate and analyze a 3D biomimetic multicellular immunogenic tumor model. The key objectives are to: (1) establish multiple levels of hypoxia within the tumor-chip for parallel processing; (2) investigate spatiotemporal interaction between the tumor microenvironment's cancer...
This $127,629 Project Grant, awarded by the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), supports a research project led by Harvard T.H. Chan School of Public Health to elucidate the role of both germline and somatic human leukocyte antigen (HLA) variations in cellular immunity and the efficacy of immune checkpoint inhibitor monotherapy in patients with non-small cell lung cancer. The overarching goal is to leverage multi-omic and clinical data to...
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $380,337 to the University of Washington to develop machine learning models that can optimize the design of mRNA sequences for cancer immunotherapy applications. The goal is to combine massively parallel reporter assays (MPRAs) with innovative algorithms to generate mRNA sequences that can achieve high protein expression or enable cell type-specific expression. The...
This $460,977 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to identify novel "chemo-neoepitopes" (CNEs) that can be used as immunogens to mobilize tumor-specific CD8+ T cells for immunotherapy against triple-negative breast cancer (TNBC). The research, conducted by Health Research, Inc. at the Roswell Park Division, aims to: 1) identify candidate CNE peptide sequences generated by...
This federal Project Grant award of $212,567 from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) will support a research specialist's roles in the laboratory of Dr. Timothy Chan and the leadership of the Computational Immunogenomics Platform (IGP) at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. The funding will enable the specialist to conduct computational analyses of cancer patient genomic data to advance the field of...
This Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) provides $256,487 to the Sloan-Kettering Institute for Cancer Research in New York to develop advanced predictive models for non-small cell lung cancer (NSCLC) outcomes. The research aims to improve risk stratification and clinical management of NSCLC by leveraging real-world data from sources like circulating tumor DNA sequencing, radiomics, tumor genomics, and clinical notes....

This federal Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $657,934 to The Johns Hopkins University to develop a more precise and broadly applicable algorithm for predicting personalized cancer neoantigens. The 5-year project aims to innovate in neoantigen prediction by integrating multi-omic patient data and leveraging a dataset of immunologically validated neoantigens. The research design includes creating a multi-omic neoantigen algorithm training and assessment resource, as well as developing a novel deep learning-based neoantigen prediction algorithm. This approach seeks to improve the precision and clinical utility of neoantigen-based cancer immunotherapies and provide open community resources to promote wider application and innovation in the field. The project commenced on Apr 1, 2025 and is expected to be completed by Mar 31, 2030.

Generated 4/8/25, 5:07 AM